The smart ring category has evolved from an experimental subsegment of personal wellness hardware into a fiercely contested consumer technology sector. On October 22nd, 2026, market pioneer Ouraring Inc. escalated its long-running intellectual property offensive against Bengaluru-based challenger Ultrahuman by filing a patent infringement complaint in the U.S. District Court for the Eastern District of Texas. The lawsuit targets Ultrahuman’s redesigned flagship wearable, the

At its October 2026 Open@Epic executive gathering, Epic Systems formally announced "Connectors," an integration technology enabling autonomous and semi-autonomous artificial intelligence agents to search for data and execute operational actions across external, third party software environments. For nearly two decades, healthcare interoperability has concentrated on data liquidity, the passive, transactional exchange of clinical records facilitated by Health Level Seven (HL7)

Nelson Advisors: Will more Digital MSK companies IPO after Hinge Health's share price more than trebled in 2026? A $32 stock is now a $107 stock. Seventeen months after it listed at $32 a share, Hinge Health traded as high as $107.44 on 20th October 2026, valuing the company at roughly $8.7 billion. That is about x3.3 times the IPO price and more than three times the $2.6 billion the company was worth on the day it priced. For a digital health IPO, that is not just a good ou

Mid October 2026, the United States District Court for the District of Massachusetts ordered the dismissal with prejudice of all claims and counterclaims in OpenEvidence, Inc. v. Doximity, Inc. et al. (Civil Action No. 1:25-cv-11802-RGS). Presided over by U.S. District Judge Richard G. Stearns, the order terminated a bitter corporate clash between two premier healthcare technology enterprises competing to dominate the clinical point of care market with generative artificial i

The soft-tissue robotic-assisted surgery landscape is undergoing a structural realignment. For more than two decades,Intuitive Surgical maintained near-exclusive hegemony over general, urological, and gynecological robotic procedures through its da Vinci ecosystem. Over recent fiscal cycles, this market structure has been disrupted by fundamental shifts:key foundational patents have expired, hospital systems have faced mounting capital expenditure pressures, and surgical case

Our report sets out to explain that paradox and to help founders, investors and operators navigate it. The core finding is concentration. Galen Growth’s data show European digital health venture funding reaching $6.2 billion in 2025, up 15 per cent year-on-year and the fastest growth of any region globally.

Short answer: the first wave has started, but the spree has not. What we are seeing in October 2026 is the opening act. A handful of small, adjacency driven deals have closed. Two category leaders have raised enough capital to buy things. The NHS has begun to buy in bulk, which changes who survives. Regulation has become a real fixed cost. The conditions for a busier twelve to eighteen months are in place, but a "spree" is a forecast, not a fact and we will try to keep the tw